Discovery
First-in-class molecules and new biology — small molecules, biologics, gene & cell.
Taiho Ventures is the corporate venture arm of Taiho Pharmaceutical — a $400M fund investing in early-stage biotech, novel platforms, and the rare modalities that will define the next decade of medicine.
We do not run a thematic fund. We invest where Taiho Pharmaceutical's sixty years of operating experience can compound a founder's progress — across four well-defined doors.
First-in-class molecules and new biology — small molecules, biologics, gene & cell.
Foundational platforms that compound and shorten the path from target to clinic.
Strategic carve-outs from the Taiho pipeline ready for an independent journey.
Opportunistic — diagnostics, devices, and digital health near our therapeutic areas.
We strive to improve human health and contribute to a society enriched by smiles.
The pledge is older than most of the molecules we've ever shipped. It is also what governs every term sheet we issue, every board seat we take, and every founder we choose to walk alongside.
Send us your deck and a hypothesis. We respond to every submission within two weeks — no warm intro required.